Carcinoma diagnosis and treatment, based on ODC1 genotype

US9121852B2 · kind B2 · utility

Assignees

• Arizona Board of Regents on Behalf of the University of Arizona · US
• THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, A CALIFORNIA CORPORATION · US

Inventors

• Eugene Gerner · Tucson, US
• Jason A. Zell · Dana Point, US
• Christine E. McLaren · Irvine, US
• Frank L. Meyskens, Jr. · Irvine, US
• Hoda Anton-Culver · Irvine, US
• Patricia A. Thompson · Tucson, US

Key dates

• Filing date: Dec 10, 2012
• Grant date: Sep 1, 2015
• Expiry date: Apr 11, 2033

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2800/52
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides methods and kits a) for predicting colorectal cancer patient survival, as well as the survival of patients harboring other invasive cancers where cellular proliferation and carcinogenesis is linked, in part, to high levels of ODC activity and increased cellular polyamine contents, and b) for selecting the corresponding treatment options for such patients based on the allelic nucleotide sequence or SNP at position +316 of the ODC1 promoter gene as well as cancer treatment methods, in each case, which include the determination of the ODC1 promoter +316 position genotype, as a means to guide treatment selection.